2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP02.16

EP02.16 - Yintao Li

Pdf Summary

A study conducted by researchers from Shandong Cancer Hospital and Institute explored the benefits of adjuvant treatment post-neoadjuvant immunotherapy combined with chemotherapy (NICT) and surgery in non-small cell lung cancer (NSCLC) patients. The study aimed to address the ongoing debate over the optimal postoperative adjuvant therapy for these patients.<br /><br />This retrospective study involved 209 NSCLC patients who had undergone NICT and surgery, and they were divided into two groups for further adjuvant therapy. One group received chemotherapy alone (Chemo group), while the other was given a combination of chemotherapy and immunotherapy (ImmunoChemo group). Researchers primarily focused on analyzing the disease-free survival (DFS) and overall survival (OS) rates of these two groups.<br /><br />The findings revealed that the ImmunoChemo group exhibited significant advantages in both DFS and OS. Specifically, the DFS rates for the ImmunoChemo group at 1 and 2 years were notably higher at 94.4% and 69.7%, respectively, as compared to 70.8% and 58.4% for the Chemo group. The overall survival at 3 years was also superior in the ImmunoChemo group at 78.9% versus 64.6% for the Chemo group. For patients who did not achieve pathological complete remission (Non-pCR), the ImmunoChemo group showed even greater improvements in survival metrics.<br /><br />The study concluded that adjuvant therapy combining chemotherapy and immunotherapy is markedly more effective than chemotherapy alone for NSCLC patients post-NICT and surgery, particularly in those not achieving complete postoperative pathological remission (Non-pCR). This study highlights the potential of combined adjuvant therapy to significantly improve survival outcomes in these patients.

Keywords

NSCLC

adjuvant therapy

immunotherapy

chemotherapy

disease-free survival

overall survival

pathological complete remission

retrospective study

Shandong Cancer Hospital

non-small cell lung cancer